Is coadministration of alendronate and nonsteroidal antiinflammatory drugs an unacceptable risk? [3]

Journal of Clinical Rheumatology

Volumn 8, Issue 5, 2002, Pages 288-290

  Rothschild, Bruce M ^a   Helbling II, Mark ^a  

^a ARTHRITIS CENTER OF NORTHEAST OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITONIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; RISEDRONIC ACID; SALCATONIN;

CLINICAL TRIAL; DRUG EFFECT; ENDOSCOPY; ESOPHAGUS INJURY; GASTROINTESTINAL SYMPTOM; HEMOGLOBIN DETERMINATION; HUMAN; LETTER; OSTEOPOROSIS; PRIORITY JOURNAL; RISK; STOMACH ULCER;

EID: 0036790213     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124743-200210000-00018     Document Type: Letter

References (13)

1. McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents post-menopausal bone loss in women without osteoporosis. Ann Intern Med 1998;128:253-61.
2. Saag KG, Emkey R, Schnitzer TJ. Alendronate for the prevention and treatment of glucocorticoid induced osteoporosis. N Engl J Med 1998; 339:292-9.
3. de Groen PC, Lubbe DF, Hirsch L, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21.
4. Levine J, Nelson D. Esophageal stricture associated with alendronate therapy. Am J Med 1997;102:489-91.
5. Graham DY, Malaty M. The combination of alendronate and naproxen is synergistic regarding the production of gastric ulcers. Arthritis Rheum 1999;42:S291.
6. Rothschild BM. Alendronate safety questioned. Arch Intern Med 2000;160:1702.
7. Blank MA, Ems BL, Gibson GW, et al. Nonclinical model for assessing gastric effects of biphosphonates. Dig Dis Sci 1997;42:281-8.
8. Lanza FL, Hunt RH, Thomson AB, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterol 2000;119:631-8.
9. Kelly R, Taggart H. Incidence of gastrointestinal side effects due to alendronate is high in clinical practice. Brit Med J 1997;315:1235.
10. Park B-J, Clouse J, Shatin D, et al. Incidence of adverse oesophageal and gastric events in alendronate users. Pharmacoepidemiol Drug Safety 2000;9:371-6.
11. Lichtenberger LM, Romero JJ, Gibson GW, et al. Effect of biphosphonates on surface hydrophobicity and phosphatidyl choline concentration of rodent gastric mucosa. Dig Dis Sci 2000;45:1792-801.
12. Levine MA, Grootendorst P. Proportion of osteoporotic post-menopausal women at increased risk for upper GI adverse events associated with biphosphonate therapy. Pharmacoepidemiol Drug Safety 2000;9:367-70.
13. Adachi JD, Adami S, Miller PD, et al. Tolerability of risedronate in alendronate-intolerant postmenopausal women. Amer Coll Gastroenterol 65th Scientific Meeting 10/14-15/00, New York City, 815 (meeting presentation).